Results from the 32-week, phase 3 DISCREET study of apremilast in patients with moderate to severe genital psoriasis

Psoriasis

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

J Am Acad Dermatol

Man X, Zaharieva K, Pulka G, Żebrowska A, Deng Y, Mekokishvili L, Yang X, Qi Y, Gu C, Dong Q, Zheng M

doi: 10.1016/j.jaad.2025.08.005

Psoriasis

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

J Am Acad Dermatol

Blauvelt A, Arenberger P, Sauder MB, Couvillion M, Rubio RG, Vlahakis NE, Ucpinar S, Ma G, Hitraya E, Tilley MK, Papp KA, STRIDE investigators

doi: 10.1016/j.jaad.2025.07.013

Psoriasis

Efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial

Br J Dermatol

Paller AS, Fiorillo L, Becker E, Armesto S, Kontzias A, Oberoi RK, Zhang W, Amouzadeh H, Zhang Z, Arkin L

doi: 10.1093/bjd/ljaf305

Psoriasis

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

J Eur Acad Dermatol Venereol

Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, Bansal A, Dahale SS, Martin R, Paguet B, Magnolo N, Kingo K

doi: 10.1111/jdv.70155

Atopic Dermatitis

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Br J Dermatol

Gooderham M, Torres T, Imafuku S, Rademaker M, Prajapati VH, Tsianakas A, Murrell DF, Owczarek W, Han Y, Lee WJ, Levy G, Ibrahim N, Moreira A, Shams K

doi: 10.1093/bjd/ljaf236

Psoriasis

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

J Eur Acad Dermatol Venereol

Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J, BE SHINING Study Group

doi: 10.1111/jdv.70350

Acne

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

J Am Acad Dermatol

Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG

doi: 10.1016/j.jaad.2025.11.031

Further Publications Immunology

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study

J Allergy Clin Immunol Pract

Yang X, Wang L, Huang K, Tang W, Berame EJ, Park HS, Hunter G, Jiang W, Wu CC, Min CW, Domek-Zielinska K, Lal H, Molfino NA, Ponnarambil SS, Zhong N

doi: 10.1016/j.jaip.2025.07.046

Atopic Dermatitis

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)

Br J Dermatol

Warren RB, de Bruin-Weller M, Tsianakas A, Khemis A, Szepietowski JC, Hong HC, Mihaylov Y, Falqués M, Agell H, Massana E, Gil EG, Coll R, Weidinger S

doi: 10.1093/bjd/ljaf285

Related content

A Phase 3, Randomized, Double-blind, Active-controlled Clinical Study to Compare BAT2206, a Ustekinumab Biosimilar, with Ustekinumab Reference Product in Patients with Moderate-to-severe Psoriasis: Treatment Period 2 Results (Post Week 28 to Week 52)

Highly selective, allosteric inhibition of TYK2 with oral ESK-001 in patients with moderate-to-severe plaque psoriasis: Results from STRIDE, a 12-week, randomized, double-blinded, placebo-controlled, dose-ranging Phase 2 study

Efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial

Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results

Efficacy and Safety of Upadacitinib Dose Escalation and Reduction in Adult Patients With Moderate-To-Severe Atopic Dermatitis: Results of a Randomized, Blinded, Treat-To-Target, Multicenter Phase 3b/4 Study (Flex Up)

Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study

Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension

Efficacy and Safety of Tezepelumab in Adults With Severe, Uncontrolled Asthma in Asia: Results From the Phase 3 DIRECTION Study

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage)